Rangering i aksjer
#37553
Peak Bio, Inc. is a biopharmaceutical firm currently in the clinical... Peak Bio, Inc. is a biopharmaceutical firm currently in the clinical development phase, committed to devising treatments for critical, unmet medical needs in the realms of oncology and inflammatory disorders. The company harnesses its unique, proprietary toxin—known as PH-1 or Thailanstatin—a spliceosome modulator, to create its inaugural range of innovative Antibody-Drug Conjugate (ADC) therapies designed for cancer patients facing significant challenges. Additionally, Peak Bio's leading investigational drug, PHP-303, a small molecule, is on the verge of commencing a Phase II dose clinical trial for the rare condition Alpha1 anti-trypsin deficiency (AATD). The company's operations are situated in Palo Alto, California.
Aksjekurs
$0.07
Sist synkronisert: 2024-11-12
Handel Peak Bio, Inc. (PKBO)
Pris PKBO pris med markedsverdi på B
Markedsverdi av Peak Bio, Inc.(PKBO)
Markedsverdi: $1.62M
Per August 2026 har Peak Bio, Inc. en markedsverdi på $1.62M. Dette gjør Peak Bio, Inc. til det 37553rd mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Peak Bio, Inc. fra 2021 til 2026
PKBO sammenlignet med topp 5 mest populære stocks
| Pris på PKBO |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.452T
|
+336,854,984.03%
|
|
|
|
|
$4.490T
|
+277,425,214.66%
|
|
|
|
|
$4.162T
|
+257,182,948.93%
|
|
|
|
|
$3.676T
|
+227,150,429.30%
|
|
|
|
|
$2.833T
|
+175,045,381.37%
|
